Pancreatic Cancer Research

ResearcherVanderbilt University Medical CenterNo recent work listed

Laura Williams Goff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6719-1479; OpenAlex author ID A5088976086. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 2, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper

Papers 5

  1. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  2. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. First author DOI 10.1007/s10637-017-0519-z↗
  3. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000377↗
  4. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.04.013↗
  5. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. First author DOI 10.1002/cam4.208↗

Trials 2

  1. Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer… Principal investigator NCT00987766↗
  2. Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorect… Principal investigator NCT00397384↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan D. Berlin · 5 shared papers, 2014–2019 · strength 0.33
  2. Dana Backlund Cardin · 4 shared papers, 2014–2018 · strength 0.26
  3. Nipun B. Merchant · 3 shared papers, 2016–2019 · strength 0.20
  4. Thomas E. Yankeelov · 2 shared papers, 2016–2018 · strength 0.13
  5. Emily W. Chan · 2 shared papers, 2014–2018 · strength 0.12
  6. Ramya Thota · 1 shared paper, 2018 · strength 0.09
  7. Eric Peter Tamm · 1 shared paper, 2019 · strength 0.07
  8. Robert A. Wolff · 1 shared paper, 2019 · strength 0.07
  9. Elliot Newman · 1 shared paper, 2019 · strength 0.07
  10. Eileen Mary O'Reilly · 1 shared paper, 2019 · strength 0.07
  11. Vikram Deshpande · 1 shared paper, 2019 · strength 0.07
  12. Mitchell C. Posner · 1 shared paper, 2019 · strength 0.07
  13. Douglas B. Evans · 1 shared paper, 2019 · strength 0.07
  14. Hedy Lee Kindler · 1 shared paper, 2019 · strength 0.07
  15. Malcolm J. Moore · 1 shared paper, 2019 · strength 0.07
  16. Peter W. T. Pisters · 1 shared paper, 2019 · strength 0.07
  17. Dushyant V. Sahani · 1 shared paper, 2019 · strength 0.07
  18. Alice Chia-Chi Wei · 1 shared paper, 2019 · strength 0.07
  19. Alexander A. Parikh · 1 shared paper, 2016 · strength 0.05
  20. Emily W. Chan · 1 shared paper, 2016 · strength 0.05
  21. A. Bapsi Chakravarthy · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.